Literature DB >> 15247082

Biogerontologists' duty to discuss timescales publicly.

Aubrey D N J de Grey1.   

Abstract

Aging is unpopular with the general public-but, it would seem, only up to a point. Treatments that claim (sometimes justifiably) to extend the total and/or healthy life span of elderly people, or even just make them look younger, are welcomed with open wallets throughout the world. If, however, one suggests to the typical nonbiologist-or even to the typical nongerontologist biologist-that we should therefore aim, in due course, to take this desire to its logical conclusion and bring aging under the same degree of control that we currently have over most infectious diseases, one is nearly always met with strong and sometimes strident opposition. I argue here that the prevalence of this outright irrationality is largely the fault of gerontologists themselves. Most people harbor a deep-seated fear of profound change in their lives and embrace it only after extensive soul-searching to convince themselves of its benefit. It cannot and should not be denied that a postaging world would be as profoundly different from today's as we can imagine. Hence, when given the opportunity to postpone sober consideration of its pros and cons, most people leap at that opportunity. It is provided to them by the nearly universal refusal of gerontologists to speculate about the timescales within which truly effective rejuvenation therapies may be developed. I suggest that this reticence, while appropriate in purely scientific fields, is hugely irresponsible in a biomedical discipline, because of its potential to delay the development of such therapies by denying them the funding that would be forthcoming if society had greater optimism concerning their foreseeability. Arguments that such funding, and/or the public's trust in scientists, would be short-lived if timescale predictions were not borne out are too flimsy to outweigh this. A further danger is the avoidable loss of life following the development of rejuvenation therapies that would result from inadequate ability to provide them universally; here again, scientists today can minimize this loss of life by agitating for forward planning by government, which will only occur when policymakers' minds are concentrating on timescale predictions.

Entities:  

Mesh:

Year:  2004        PMID: 15247082     DOI: 10.1196/annals.1297.100

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  Listening to public concerns about human life extension. The public view of life-extension technologies is more nuanced than expected and researchers must engage in discussions if they hope to promote awareness and acceptance.

Authors:  Brad Partridge; Jayne Lucke; Wayne Hall
Journal:  EMBO Rep       Date:  2010-09-10       Impact factor: 8.807

2.  Who wants to live forever?

Authors:  Jayne C Lucke; Wayne Hall
Journal:  EMBO Rep       Date:  2005-02       Impact factor: 8.807

Review 3.  Anticipating the anti-ageing pill. Lessons from the history of the oral contraceptive pill and hormone replacement therapy.

Authors:  Jayne C Lucke; Phillippa C Diedrichs; Bradley Partridge; Wayne D Hall
Journal:  EMBO Rep       Date:  2009-01-16       Impact factor: 8.807

4.  Selling anti-aging research: the perils of mixed messages.

Authors:  Aubrey D N J de Grey
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.